XLN306 induces apoptosis in human breast carcinoma MX-1 cells  by Jin, Jing et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2011;1(2):84–882211-3835 & 2011 In
hosting by Elsevier B
Peer review under re
doi:10.1016/j.apsb.20
nCorresponding au
E-mail address: cwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
XLN306 induces apoptosis in human breast carcinoma
MX-1 cellsJing Jin, Li-na Zhu, Hai-jing Zhang, Yan Li, Yi Zhang, Wan-qi Zhou,
Bai-ling Xu, Xiao-guang ChennDepartment of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
College (State Key Laboratory of Bioactive Substances and Functions of Natural Medicines), Beijing 100050, China
Received 23 March 2011; revised 25 April 2011; accepted 17 May 2011KEY WORDS
XLN306;
Breast carcinoma;
Antitumor activity;
Apoptosisstitute of Materia M
.V. All rights rese
sponsibility of Inst
11.06.003
thor. Tel.: þ86 10
henxg@imm.ac.cnAbstract XLN306 is a novel synthetic quinazoline derivative with potentially useful anticancer
activity. In previous research, we showed that XLN306 is highly cytotoxic to many tumor cell lines.
This paper reports an investigation of this cytotoxicity in a number of human carcinoma cell lines.
The results show that human breast carcinoma MX-1 cells are extremely sensitive to XLN306 and
that the cytotoxicity is due to dose- and time-dependent apoptosis as conﬁrmed by DAPI stain and
DNA fragmentation analysis. Both extrinsic and intrinsic pathways are involved in the apoptosis
process. The ﬁndings indicate that XLN306 has apoptotic induction activity and may be useful for
the management of various cancers, especially breast carcinoma.
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Cytotoxicity of XLN306 to MX-1 cells 851. Introduction
Cancer, characterized by uncontrolled growth of abnormal
cells, is undoubtedly one of the most serious and potentially
life-threatening human diseases1. In the past, the scientiﬁc
community has produced remarkable advances in our under-
standing of cancer biology, including the realization that
apoptosis (programmed cell death) of cancer cells is tightly
regulated and critical for the development of the disease2.
Currently, most cancer chemotherapeutic agents exert their
antitumor effects by triggering apoptosis in cancer cells3.
Apoptosis is an evolutionary conserved process that occurs
in various physiological and pathological situations. It is
characterized by a number of morphological and biochemical
features, including cell shrinkage, nuclear DNA fragmentation
and membrane blebbing4. The two main routes of apoptosis
are the extrinsic and intrinsic (mitochondrial) pathways, both
of which involve caspase activation5,6.
XLN306 is a new cytotoxic compound with potential as an
anticancer drug. In this paper, we report the effects of
XLN306 on different human cancer cell lines and show that
the human breast cancer cell line, MX-1, is the most sensitive
to XLN306. In terms of the mechanism of the cytotoxic
action, XLN306 was shown to cause apoptosis in MX-1 cells
as determined by cell morphology, DNA ladder assay and
protein expression.2. Materials and methods
2.1. Chemicals
XLN306 was synthesized and supplied as a yellow solid by the
Institute of Materia Medica, Chinese Academy of Medical
Sciences & Peking Union Medical College (Fig. 1). The
compound was dissolved in DMSO to give a 50 mmol/L stock
solution, which was stored at 4 1C when not in use. The purity
of XLN306 was 495% as shown by 1H NMR spectroscopy.2.2. Cell culture
The following human carcinoma cell lines were obtained from
ATCC: breast MX-1 and MCF7 cells; pancreatic Bxpc3 cells;
hepatocellular Bel7402 and HepG2 cells; lung A549 cells;
colon HT29 and HCT8 cells; and ovarian A2780 cells. All
cell lines were maintained in DMEM medium (Gibco, Grand
Island, NY, USA) containing 10% heat-inactivated newborn
calf serum (PAA) at 37 1C under 5% CO2.Figure 1 Structure of XLN306.2.3. Cytotoxicity
Cytotoxicity was measured using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief,
cells were seeded in 96-well microplates at a density of 4 103–
1.2 104 cells/well and cultured for 24 h. They were then
treated with XLN306 for 12, 24, 48, 72 or 96 h after which
MTT (0.5 mg/mL) was added and the plates were incubated
for 4 h in an incubator. The medium was removed and any
formazan produced dissolved in DMSO. The optical density
was then measured at 570 nm using a spectrophotometer
(Thermo Multiskan MK3, Germany).
2.4. Flow cytometry
Cells treated with or without XLN306 at various concentra-
tions were collected by trypsinization, washed twice with
phosphate-buffered saline (PBS) and ﬁxed in ice-cold 70%
(v/v) ethanol at 20 1C for 24 h. After centrifugation, the cell
pellets were resuspended in 1 mL propidium iodide (PI)
solution (50 mg/mL PI, 50 mg/mL RNase A, 0.03% Triton
X-100 and 0.01% sodium citrate in PBS) and incubated for
30 min at 37 1C. DNA histograms were obtained by ﬂuores-
cence activated cell sorting (FACS) analysis.
2.5. Electrophoresis of DNA fragments
MX-1 cells (1 106) pretreated with or without XLN306 for
24 h were lysed in 200 mL lysis buffer (10 mmol/L EDTA;
50 mmol/L Tris–HCl pH 8.0; 0.5% sodium lauryl sulfate;
100 mg/mL proteinase K) at 37 1C for 12 h and subsequently
incubated with RNase (50 mg/mL) at 37 1C for an additional
1 h. DNA in the lysate was extracted with an equal volume of
phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) and then
with chloroform. DNA was precipitated with two volumes of
ethanol in the presence of 0.3 mol/L sodium acetate. After
centrifugation at 13,000 rpm for 15 min, the DNA pellets were
washed with 70% ethanol, air dried and resuspended in 20 mL
TE buffer (10 mmol/L Tris–HCl and 1 mmol/LEDTA pH
8.0). DNA was separated on 1% agarose gel containing
0.5 mg/mL ethidium bromide and photographed using a UV
light sequence detection system.
2.6. DAPI staining
After incubating MX-1 cells with or without XLN306 for 24 h,
the cells were stained with DAPI (10 mg/mL in PBS) for
30 min and then ﬁxed with 4% paraformaldehyde for 15 min
in the dark. After washing with PBS, cell morphology was
observed using a ﬂuorescence microscope (Olympus BX51,
Japan).
2.7. Protein expression by Western blot analysis
Total cellular protein was extracted using lysis buffer and protein
concentration measured using the Bio-Rad protein assay. An
equal amount of protein was separated using 10% and 12% SDS-
PAGE and transferred to nitrocellulose membranes (Amersham,
Bucks, UK). The membranes were blocked with 5% skimmed
milk in PBS and incubated overnight with primary anti-
bodies, followed by horseradish-peroxidase-conjugated antibodies
Jing Jin et al.86at room temperature. b-Actin was used as internal positive
control. Primary antibodies included Fas, FasL, Bcl-2, Bax,
cytochrome C, b-actin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), p-AKT (Ser473), AKT, caspase-3 and cleaved
caspase-3 (Cell Signaling Technology, Danvers, MA, USA).Table 1 Cytotoxicity (96 h) of XLN306
against various human cancer cell lines.
Tumor cell line IC50 (mmol/L)
MCF7 3.08
MX-1 2.25
Bxpc3 5.07
Bel7402 3.22
HepG2 7.66
HT29 5.02
HCT8 3.6
A549 62.7
A2780 5.6
Figure 2 Flow cytometric analysis of propidium iodide stained DNA of
with different concentrations of XLN306 for 24 h; B: MX-1 cells were tr
sub-G1 fraction of XLN306-treated cells provides an estimate of the nuSignals were visualized using an enhanced chemiluminescence
system (Amersham).3. Results
3.1. Cytotoxicity of XLN306
Based on previous studies, a small panel of human cancer cell
lines was used to investigate the cytotoxicity of XLN306. As
shown in Table 1, the human breast cancer cell line, MX-1, was
the most sensitive to XLN306 with an IC50 of 2.25 mmol/L at
96 h. To further investigate the cytotoxicity of XLN306, MX-1
cells were treated with a range of concentrations of XLN306 for
12, 24, 48 and 72 h. XLN306 showed dose- and time-dependent
cytotoxicity to MX-1 cells with IC50 values of 13.12, 10.72, 5.6
and 4.99 mmol/L at 12, 24, 48 and 72 h, respectively.
3.2. Mechanism of XLN306 cytotoxicity
To gain an insight into the mechanism of XLN306 cytotoxi-
city, MX-1 cells were examined by ﬂow cytometry followingMX-1 cells following XLN306 treatment. A: MX-1 cells were treated
eated with 25 mmol/L XLN306 for different time; C: Increase in the
mber of apoptotic cells (data are mean 7SD, n¼3).
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a dose- and time-dependent accumulation of MX-1 cells in the
sub-G1 phase, which suggests that it causes cell death by the
induction of apoptosis.
To further investigate the apoptotic effect, morphological
analysis by ﬂuorescence microscopy after DAPI staining was
employed. After 24 h exposure to XLN306 at concentrations
of 5, 10 and 20 mmol/L, MX-1 cells showed typical apoptotic
characteristics including cell shrinkage, chromatin condensa-
tion and fragmentation. In contrast, cells in the untreated
group showed normal morphology with blue nuclei (Fig. 3).
In addition, analysis of DNA fragmentation showed that
treatment of MX-1 cells with XLN306 resulted in a dose-
dependent and statistically signiﬁcant increase in DNA frag-
mentation compared to the control (Fig. 4). All these results
indicate that the growth inhibition of MX-1 cells by XLN306
is due to the induction of apoptosis.Figure 4 DNA fragmentation after exposure to XLN306 for 24 h
at concentrations of line 1: 0 mmol/L, line 2: 5 mmol/L, line 3:
10 mmol/L and line 4: 20 mmol/L. DNA was extracted and
fragments were separated by electrophoresis on 1% agarose gel
and detected with ultraviolet irradiation.3.3. Protein expression
It is well known that cellular apoptosis is mainly associated
with alterations in two signaling pathways, namely the
extrinsic and intrinsic pathways. To investigate the mechanism
of apoptosis induction by XLN306, the protein expression of
the two pathways was investigated.
The extrinsic pathway is also known as the death receptor
pathway. Death receptors are members of the tumor necrosis
factor (TNF) receptor gene superfamily, which consists of
more than 20 proteins. Of these, Fas (CD95) is the most
famous with FasL (CD95L) as its corresponding ligand7. As
shown in Fig. 5, the expression of FasL in MX-1 cells treated
with XLN306 (5–20 mmol/L for 12 h) exhibits a signiﬁcant
dose-dependent increase while the expression of Fas increases
only at the highest dose of XLN306 (20 mmol/L).Figure 3 Changes in the morphology of MX-1 cells treated with
XLN306 ((A) 0 mmol/L, (B) 5 mmol/L, (C) 10 mmol/L and (D)
20 mmol/L) for 24 h followed by staining with DAPI and examina-
tion by ﬂorescence microscopy (magniﬁcation 200 ). Apoptotic
cells with fragmented nuclei are observed after XLN306 treatment.
Figure 5 Western blot analysis using antibodies speciﬁc for
proteins in the extrinsic apoptotic pathway (Fas and FasL) in
MX-1 cells exposed to XLN306 (5, 10 and 20 mmol/L) for 12 h.
b-Actin levels are shown as an internal control.The intrinsic pathway is also known as the mitochondrial
pathway. As shown in Fig. 6, Bcl-2 exhibits a dose-dependent
decrease in MX-1 cells treated with XLN306 (5–20 mmol/L
for 12 h) while Bax, one of the proapoptotic members of the
Bcl-2 family8, increased after treatment with 5 and 10 mmol/L
XLN306 compared to the control. Total cytochrome c and
cleaved caspase-3 (activated caspase-3) also exhibited dose-
dependent increases on treatment with XLN306.
Furthermore, accumulated evidence shows that survival factor
AKT exerts an anti-apoptotic action by regulation of molecules
at both pre- and post-mitochondrial levels9–11. Our results
(Fig. 6) show that the expression of p-AKT (Ser473) in MX-1
Figure 6 Western blot analysis using antibodies speciﬁc for
proteins in the intrinsic apoptotic pathway (Bcl-2, Bax, cyto-
chrome C, caspase-3, cleaved caspase-3, p-AKT (Ser473), AKT)
in MX-1 cells exposed to XLN306 (5, 10 and 20 mmol/L) for 12 h.
b-Actin levels are shown as an internal control.
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signiﬁcantly while AKT (pan) stayed at the same level.4. Discussion
XLN306 is a novel synthetic compound that exerts a speciﬁc
activity against many human cancer cell lines, especially
MX-1. In order to illuminate its mechanism of action, ﬂow
cytometric analysis was carried out. The results show that
XLN306 induces cell apoptosis in a dose- and time-dependent
manner and produces apoptotic bodies and DNA ladders.
To investigate the apoptosis signaling pathway induced by
XLN306, the expression of proteins related to the extrinsic
and intrinsic pathways was investigated. The Fas/FasL system
has been implicated in chemotherapy-induced tumor cell death
in a number of studies. Treatment with anticancer drugs
including doxorubicin, etoposide and cisplatin can trigger an
increase in FasL expression, which stimulates the receptor
pathway in an autocrine or paracrine manner by binding to
Fas12–15. In our study, we observed increases in the expression
of Fas and more particularly FasL, the latter being dose-
dependent. This indicates that the extrinsic pathway is
involved in the induction of apoptosis by XLN306.
Interestingly, changes in the expression of membrane-
bound and soluble FasL were not identical. Membrane-bound
FasL increased on treatment with 5 and 10 mmol/L XLN306
but decreased on treatment with 20 mmol/L XLN306. In
contrast, soluble FasL was relatively unaltered on treatment
with 5 and 10 mmol/L XLN306 but increased dramatically on
treatment with 20 mmol/L XLN306. This indicates that
XLN306 induces FasL by different mechanisms at different
concentrations, a result that requires further research.
In the intrinsic pathway of apoptosis, caspase activation is
closely linked to permeabilization of the outer mitochondrial
membrane by proapoptotic members of the Bcl family16. Bcl-2
protein, located on the outer mitochondrial membrane, is
important for suppression of mitochondrial manifestations ofapoptosis17,18. The release of cytochrome c from mitochondria
directly triggers caspase-3 activation19. In this study, treatment
with XLN306 led to a decrease in Bcl-2, an increase in the release
of cytochrome c and ﬁnally caspase-3 activation. This suggests
that the intrinsic pathway is also involved in the induction of
apoptosis by XLN306. Furthermore, 20 mmol/L XLN306
decreased the expression of p-AKT (Ser473), which demonstrates
that induction of apoptosis by XLN306 involves multiple targets.
In conclusion, XLN306 is a promising drug for the manage-
ment of various human cancers whose mechanism of action
involves the induction of apoptosis.
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